These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32275069)

  • 1. Financial analysis of large-volume delayed sampling to reduce bacterial contamination of platelets.
    Kacker S; Katz LM; Ness PM; Bloch EM; Goel R; Gehrie EA; Lokhandwala PM; Tobian AAR
    Transfusion; 2020 May; 60(5):997-1002. PubMed ID: 32275069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions.
    Kacker S; Bloch EM; Ness PM; Gehrie EA; Marshall CE; Lokhandwala PM; Tobian AAR
    Transfusion; 2019 Apr; 59(4):1291-1299. PubMed ID: 30623459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017.
    Kundrapu S; Srivastava S; Good CE; Lazarus HM; Maitta RW; Jacobs MR
    Transfusion; 2020 May; 60(5):974-985. PubMed ID: 32357261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial contamination rate of platelet components by primary culture: a systematic review and meta-analysis.
    White SK; Schmidt RL; Walker BS; Metcalf RA
    Transfusion; 2020 May; 60(5):986-996. PubMed ID: 32181889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.
    Prioli KM; Karp JK; Lyons NM; Chrebtow V; Herman JH; Pizzi LT
    Appl Health Econ Health Policy; 2018 Dec; 16(6):889-899. PubMed ID: 30062464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of FDA platelet bacterial guidance compliance options: Comparison of single-step strategies.
    Prioli KM; Abersone I; Kopko PM; Herman JH; Custer B; Pizzi LT
    Transfusion; 2022 Feb; 62(2):365-373. PubMed ID: 34997763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States.
    Earnshaw S; Beyhaghi H; McDade C; Purser M; Marriott R; Daane L; Le Coent V; Yang J; Toback S
    Transfusion; 2021 Oct; 61(10):2885-2897. PubMed ID: 34289101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the sample time of secondary bacterial culture on the risk of exposure to contaminated platelet components: A mathematical analysis.
    Moore RA; Schmidt RL; Metcalf RA
    Transfusion; 2021 Mar; 61(3):873-882. PubMed ID: 33429466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efforts Toward Elimination of Infectious Agents in Blood Products.
    Jacquot C; Delaney M
    J Intensive Care Med; 2018 Oct; 33(10):543-550. PubMed ID: 29562814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions.
    Bloch EM; Marshall CE; Boyd JS; Shifflett L; Tobian AAR; Gehrie EA; Ness PM
    Transfusion; 2018 Jul; 58(7):1647-1653. PubMed ID: 29607515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The negative secondary test for bacterial contamination: reducing the risk of septic transfusion reactions from platelets.
    Tomasulo PA; Jacobs MR
    Transfusion; 2017 Aug; 57(8):2054-2055. PubMed ID: 28656692
    [No Abstract]   [Full Text] [Related]  

  • 12. A national survey of hospital-based transfusion services on their approaches to platelet bacterial risk mitigation in response to the FDA final guidance for industry.
    Lu W; Delaney M; Dunbar NM; Rossmann SN; Fung M
    Transfusion; 2020 Aug; 60(8):1681-1687. PubMed ID: 32564352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost implications of implementation of pathogen-inactivated platelets.
    McCullough J; Goldfinger D; Gorlin J; Riley WJ; Sandhu H; Stowell C; Ward D; Clay M; Pulkrabek S; Chrebtow V; Stassinopoulos A
    Transfusion; 2015 Oct; 55(10):2312-20. PubMed ID: 25989465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial contamination and transfusion safety: experience in the United States.
    Dodd RY
    Transfus Clin Biol; 2003 Feb; 10(1):6-9. PubMed ID: 12668181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood collection and transfusion in the United States in 1999.
    Sullivan MT; Wallace EL
    Transfusion; 2005 Feb; 45(2):141-8. PubMed ID: 15660821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial contamination of platelets for transfusion: strategies for prevention.
    Levy JH; Neal MD; Herman JH
    Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service.
    AuBuchon JP; Cooper LK; Leach MF; Zuaro DE; Schwartzman JD
    Transfusion; 2002 Jul; 42(7):855-61. PubMed ID: 12375657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of bacterial contamination of apheresis platelets in a Chinese Blood Center.
    Zhu L; Xu J; Yang X; Shen Z; Wang Y; Zhu F; Lv H; Yan L
    Transfus Med; 2009 Dec; 19(6):357-62. PubMed ID: 19719475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.
    Bell CE; Botteman MF; Gao X; Weissfeld JL; Postma MJ; Pashos CL; Triulzi D; Staginnus U
    Clin Ther; 2003 Sep; 25(9):2464-86. PubMed ID: 14604745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incremental benefit of anaerobic culture for controlling bacterial risk in platelets: a systematic review and meta-analysis.
    Corean J; White SK; Schmidt RL; Walker BS; Fisher MA; Metcalf RA
    Vox Sang; 2021 Apr; 116(4):397-404. PubMed ID: 32996621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.